TAIM
TEVA icon

TD Ameritrade Investment Management’s Teva Pharmaceuticals TEVA Stock Holding History

TD Ameritrade Investment Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,088
Closed -$10K – 603
2023
Q1 		$10K Sell
1,088
-234
-18% -$2.31K ﹤0.01% 381
2022
Q4 		$12K Sell
1,322
-304
-19% -$2.65K ﹤0.01% 372
2022
Q3 		$13K Sell
1,626
-1,118
-41% -$9.89K ﹤0.01% 364
2022
Q2 		$21K Buy
2,744
+404
+17% +$3.52K ﹤0.01% 379
2022
Q1 		$22K Buy
2,340
+588
+34% +$4.91K ﹤0.01% 410
2021
Q4 		$14K Buy
1,752
+1,359
+346% +$12.3K ﹤0.01% 454
2021
Q3 		$4K Buy
+393
New +$3.68K ﹤0.01% 539
2020
Q4 		– Sell
-393
Closed -$4K – 660
2020
Q3 		$4K Hold
393
– – ﹤0.01% 539
2020
Q2 		$5K Buy
+393
New +$4.45K ﹤0.01% 517
2019
Q2 		– Sell
-528
Closed -$8K – 678
2019
Q1 		$8K Buy
528
+51
+11% +$899 ﹤0.01% 387
2018
Q4 		$7K Buy
477
+254
+114% +$5.21K ﹤0.01% 410
2018
Q3 		$5K Buy
223
+161
+260% +$3.74K ﹤0.01% 406
2018
Q2 		$2K Buy
+62
New +$1.26K ﹤0.01% 381

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

TD Ameritrade Investment Management's TEVA Position: Q2 2023 in Review

TD Ameritrade Investment Management sold out of Teva Pharmaceuticals (TEVA) in Q2 2023, closing a stake of 1,088 shares — an estimated $10K sold.

TD Ameritrade Investment Management first reported a position in TEVA in Q2 2018 and held it in 13 quarters. The position peaked at $22K in Q1 2022. 428 funds tracked by Wall St. Rank hold TEVA as of Q2 2023.

  • TD Ameritrade Investment Management reported no remaining Teva Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • TD Ameritrade Investment Management sold 1,088 Teva Pharmaceuticals shares in Q2 2023, an estimated $10K.
  • TD Ameritrade Investment Management first reported a position in Teva Pharmaceuticals in Q2 2018 and held it in 13 quarters.
  • TD Ameritrade Investment Management's Teva Pharmaceuticals position peaked at $22K in Q1 2022.
  • 428 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2023.

Based on TD Ameritrade Investment Management's 13F filing for Q2 2023, filed 10 Aug 2023.